Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.

被引：0
|
作者：
Kang, Yixin
Zhang, Dianbao
Mi, Youjia
Niu, Xiedong
Kang, Yuan
Xie, Dongjie
Li, Wenyao
Zhang, Ce
Yang, Junqiang
Yao, Jun
机构：
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gastroenterol Oncol, Luoyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16034
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Regorafenib combined with transarterial chemoembolization and PD-1 antibody as a second-line therapy for hepatocellular carcinoma: A real-world study.
    Pan, Tao
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16167 - E16167
  • [42] Second-line drug regimens in metastatic melanoma patients based on BRAF mutation status: A Canadian real-world retrospective study.
    Bremner, Samantha
    Lapierre, Marc
    Fraelic, Arushi
    Stewart, Dave
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.
    Gupta, Shilpa
    Huang, Richard S. P.
    Stanke, Jennifer
    Hamdani, Omar
    Gjoerup, Ole
    Alexander, Brian Michael
    Levy, Mia Alyce
    Oxnard, Geoffrey R.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [44] Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
    Blomstrand, Hakon
    Batra, Atul
    Cheung, Winson Y.
    Elander, Nils Oskar
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (09): : 787 - 799
  • [45] FIRST AND SECOND LINE TREATMENT CHOICES FOR ENDOMETRIAL CANCER: ECHOS-A REAL-WORLD STUDY
    Abreu, G.
    Queiroz, J.
    Nogueira da Silva, T. L.
    Soares, C.
    Menezes, P.
    Carrizo, M.
    Scibona, P.
    Simonovich, V. A.
    Riggi, M. C.
    Saadi, J. J.
    Cravero, F.
    Jotimliansky, L.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [46] Real-world evidence on second-line treatment of fluoropyrimidine, irinotecan, and anti-VEGF antibody for metastatic colorectal cancer
    Yamanaka, T.
    Yamazaki, K.
    Hamano, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S114 - S114
  • [47] Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
    Wang, Li
    Li, Xiaolin
    Zhao, Bin
    Mei, Dan
    Jiang, Jiandong
    Duan, Jingli
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [48] A real-world clinical study of camrelizumab in the treatment of esophageal cancer.
    Sun, Guoping
    Qian, Dong
    Zhao, Dong
    Liang, Hui
    Cheng, Huaidong
    Wang, Genhe
    Wang, Fan
    Jiang, Hao
    Xu, Tengyun
    Wu, Qibing
    Zhu, Shaojin
    Xu, Dong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Liu, Yuxiao
    Guo, Xiaofan
    Xu, Peijun
    Song, Yuning
    Huang, Jing
    Chen, Xingyun
    Zhu, Wenbo
    Hao, Jihui
    Gao, Song
    CANCER BIOLOGY & MEDICINE, 2024, 21 (09) : 799 - 812
  • [50] Real-world efficacy of second-line therapies for Helicobacter pylori: a population-based study
    Guo, Chuan-Guo
    Jiang, Fang
    Li, Yueyue
    Chen, Yijun
    Wu, Jialin
    Zhang, Shutian
    Leung, Wai K.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2263 - 2272
12345